The aim of our study was to evaluate whether sarcopenia and obesity could predict the response to therapy in patients with metastatic ER+/HER2- BC, treated with CDK 4/6 inhibitors. The gene discussed is ERBB2; the disease is obesity due to melanocortin 4 receptor deficiency.